Dumping Syndrome Market Report 2024: Strategies And Recent Developments | Cardinal Health Inc., Johnson & Johnson Private Limited, Abbott Laboratories Inc., Medtronic PLC, Covidien PLC, Fujifilm Holdings Corporation

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Dumping Syndrome Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The dumping syndrome market size has grown rapidly in recent years. It will grow from $1.12 billion in 2023 to $1.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to gastric surgery procedures, increased prevalence of obesity, advancements in surgical techniques, improved diagnostic methods.

The dumping syndrome market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to weight loss surgery trends, personalized treatment approaches, nutritional and dietary interventions, telemedicine and remote monitoring. Major trends in the forecast period include minimally invasive surgical techniques, data analytics and ai, increased collaboration, preventive measures.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12991&type=smp

Market Segmentation:
The main types of diagnoses included in dumping syndrome are blood sugar tests, gastric emptying tests, medical histories and others. A blood sugar test, also known as a blood glucose test, is a medical test used to measure the concentration of glucose (sugar) in a person's blood. The various types of treatments include medication, surgery and others, which can be administered through various routes, such as oral, intravenous and others. It is used to treat various phases of diseases including the early dumping phase and the late dumping phase and used by several end users, such as hospitals and clinics, research laboratories and others.

Major Driver - Increasing Incidence Of Upper Gi Diseases Boosts The Dumping Syndrome Market
The rising prevalence of upper GI diseases is expected to propel the growth of the dumping syndrome market going forward. Upper gastrointestinal (GI) diseases refer to disorders affecting the upper part of the digestive system, including the esophagus, stomach and the first part of the small intestine (duodenum). Dumping syndrome is a condition that can occur after a person undergoes particular upper gastrointestinal (GI) surgeries, particularly those that involve the stomach, duodenum, or pyloric sphincter. For instance, in April 2023, according to the National Library of Medicine, a US-based medical library, Upper gastrointestinal bleeding (UGIB) is a frequent issue, with an estimated occurrence in 80 to 150 out of 100,000 individuals annually. The estimated mortality rates range from 2 to 15 percent. Upper gastrointestinal bleeding (UGIB) constitutes 75% of all cases of acute gastrointestinal (GI) bleeding. Therefore, the rising prevalence of upper GI diseases is driving the growth of the dumping syndrome market.

Competitive Landscape:
Major players in the dumping syndrome market are Cardinal Health Inc., Johnson & Johnson Private Limited, Abbott Laboratories Inc., Medtronic PLC, Covidien PLC, Fujifilm Holdings Corporation, Stryker Corporation, Allergan PLC, Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, Intuitive Surgical Inc., Terumo Corporation, Steris Corporation, Teleflex Medical Europe Ltd., Cook Medical Inc., Karl Storz SE & Co. KG, Conmed Corporation, Applied Medical Resources Corporation, Richard Wolf GmbH, Pentax Medical Company, GI Dynamics, EndoGastric Solutions Inc., Apollo Endosurgery Inc., EndoChoice Holdings Inc., Cousin Biotech , Mediflex Surgical Product, Asensus Surgical Inc., USGI Medical Inc., TransEnterix Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/dumping-syndrome-global-market-report

Top Trend - Innovative Non-Invasive Tools Revolutionizing Gastric Emptying Measurement In The Dumping Syndrome Market
Major companies operating in the dumping syndrome market are increasing their focus on introducing non-invasive tools for measuring gastric emptying to gain a competitive edge in the market. Non-invasive tools for measuring gastric emptying are diagnostic methods that assess the rate at which the stomach empties its contents into the small intestine without the need for invasive procedures. For instance, in September 2021, Cairn Diagnostics, a US-based life science company, launched the 13C-Spirulina Gastric Emptying Breath Test (GEBT). The test involves consuming a small amount of Spirulina labeled with a stable isotope of carbon, followed by breathing into a machine that measures the amount of carbon dioxide in the breath. The rate of carbon dioxide production is then used to calculate the rate of food emptying from the stomach. The GEBT is a safe, standardized, and convenient alternative to nuclear medicine-based gastric emptying evaluations typically conducted in a nuclear medicine center. The test can be administered in a clinical setting or via telehealth at a patient's home and is a non-invasive tool for measuring gastric emptying velocity and aiding in the diagnosis of gastroparesis.

Innovative Endoscopy Systems like EVIS X1 Revolutionize Diagnosis and Treatment of Dumping Syndrome

Companies operating in the dumping syndrome market are adopting new technological solutions, such as EVIS X1 to sustain their position in the market. The EVIS X1 endoscopy system features three new enhancements designed to assist physicians in visualizing GI bleeds and anatomical structures. For instance, in April 2020, Olympus Corporation, a Japan-based equipment and tools manufacturing company for optical and digital technologies launched EVIS X1. EVIS X1 promotes accurate screening and confident diagnosis in the identification, characterization and management of gastrointestinal problems including colorectal cancer (CRC) or bronchial diseases. These include narrow-band imaging (NBI), red dichromatic imaging (RDI), texture and color enhancement imaging (TXI) and extended depth of field (EDOF).

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Dumping Syndrome Market Characteristics
3. Dumping Syndrome Market Trends And Strategies
4. Dumping Syndrome Market - Macro Economic Scenario
5. Dumping Syndrome Market Size And Growth
…..
27. Dumping Syndrome Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.